GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actavia Life Sciences Inc (OTCPK:RASP) » Definitions » Cyclically Adjusted PB Ratio

Actavia Life Sciences (Actavia Life Sciences) Cyclically Adjusted PB Ratio : 0.45 (As of Jun. 09, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Actavia Life Sciences Cyclically Adjusted PB Ratio?

As of today (2024-06-09), Actavia Life Sciences's current share price is $0.009. Actavia Life Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $0.02. Actavia Life Sciences's Cyclically Adjusted PB Ratio for today is 0.45.

The historical rank and industry rank for Actavia Life Sciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

RASP' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 1.01
Current: 0.47

During the past years, Actavia Life Sciences's highest Cyclically Adjusted PB Ratio was 1.01. The lowest was 0.00. And the median was 0.00.

RASP's Cyclically Adjusted PB Ratio is ranked better than
65.36% of 661 companies
in the Biotechnology industry
Industry Median: 1.75 vs RASP: 0.47

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Actavia Life Sciences's adjusted book value per share data for the three months ended in Mar. 2024 was $-0.003. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.02 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Actavia Life Sciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Actavia Life Sciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actavia Life Sciences Cyclically Adjusted PB Ratio Chart

Actavia Life Sciences Annual Data
Trend Jun14 Jun15 Jun16 Mar17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 1.04

Actavia Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.75 1.26 1.04 0.40 0.40

Competitive Comparison of Actavia Life Sciences's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Actavia Life Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actavia Life Sciences's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actavia Life Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Actavia Life Sciences's Cyclically Adjusted PB Ratio falls into.



Actavia Life Sciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Actavia Life Sciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.009/0.02
=0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actavia Life Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Actavia Life Sciences's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.003/131.7762*131.7762
=-0.003

Current CPI (Mar. 2024) = 131.7762.

Actavia Life Sciences Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.001 100.560 0.001
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 -0.001 99.621 -0.001
201506 -0.001 100.684 -0.001
201509 -0.001 100.392 -0.001
201512 -0.001 99.792 -0.001
201603 -0.002 100.470 -0.003
201606 -0.007 101.688 -0.009
201609 0.122 101.861 0.158
201612 0.085 101.863 0.110
201703 0.111 102.862 0.142
201706 0.098 103.349 0.125
201709 0.000 104.136 0.000
201712 0.073 104.011 0.092
201803 0.060 105.290 0.075
201806 0.050 106.317 0.062
201809 0.045 106.507 0.056
201812 0.041 105.998 0.051
201903 0.039 107.251 0.048
201906 0.037 108.070 0.045
201909 0.037 108.329 0.045
201912 0.035 108.420 0.043
202003 0.033 108.902 0.040
202006 -0.006 108.767 -0.007
202009 -0.039 109.815 -0.047
202012 -0.041 109.897 -0.049
202103 -0.041 111.754 -0.048
202106 -0.042 114.631 -0.048
202109 -0.040 115.734 -0.046
202112 -0.036 117.630 -0.040
202203 -0.031 121.301 -0.034
202206 -0.010 125.017 -0.011
202209 -0.009 125.227 -0.009
202212 -0.010 125.222 -0.011
202303 -0.002 127.348 -0.002
202306 -0.003 128.729 -0.003
202309 -0.003 129.860 -0.003
202312 -0.003 129.419 -0.003
202403 -0.003 131.776 -0.003

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Actavia Life Sciences  (OTCPK:RASP) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Actavia Life Sciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Actavia Life Sciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Actavia Life Sciences (Actavia Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 2525, New York, NY, USA, 10170
Rasna Therapeutics Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.

Actavia Life Sciences (Actavia Life Sciences) Headlines

No Headlines